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Background: Lymphopenia commonly occurs in cancer patients and predicts poor prognosis. It is caused by radio-
and chemotherapy, with malnutrition and treatment-related oxidative stress playing key roles in its pathogenesis.
Tumour-related morbidity is reported to be associated with reduced plasma ascorbate, which is a key physiological
antioxidant and essential factor in immune function.
Method: A prospective observational study was conducted on 48 cancer patients with lymphopenia (<1500/μL) to
investigate the total lymphocyte count (TLC) during four weeks of elective adjuvant treatment with intravenous (iv)
vitamin C 7.5 g (Pascorbin®7.5 g) once a week. TLC values at baseline (just prior to start of treatment) and after
4 weeks treatment were compared using descriptive statistics.
Results: After 4 weeks iv vitamin C 7.5 g, TLC increased by a mean of 211/μL (p = 0.0018). Subgroup analyses showed
that, in patients with severe lymphopenia (n = 25) (TLC <1000/μL), the increase in TLC was greater with a mean rise of
368/μL (p = 0.0004), than in patients (n = 23) with an initial TLC of 1000–1500 (mean rise of 40/μL) (p = 0.6105). TLC
increased by at least 240/μL in half of the patients with severe lymphopenia and by more than 610/μL in 25% of
patients.
Conclusion: Our data indicate that iv high-dose vitamin C treatment increases TLC, which strongly implies improvement
of immune function, especially in patients with severe lymphopenia. Appropriately-powered, randomized,
placebo-controlled trials of iv high-dose vitamin C are now needed to define more precisely its role in the
treatment of cancer-related lymphopenia and how this impacts on the patients’ clinical prognosis.
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Severe treatment-related hematological toxicities, such
as lymphopenia, occur commonly in many cancers [1].
Drastically reduced TLC increases the risk of various
forms of infections [2]. Recent studies reveal an association
of post-treatment lymphopenia and decreased survival in
patients with solid tumours who underwent chemo- or
radiotherapy [1, 3–5]. Adjuvant treatment options are
needed to restore this reversible prognostic factor.
Ascorbate, the absorbed form of dietary vitamin C, is
an essential factor for immune cells and enhances the* Correspondence: dra.rodriguezv@yahoo.com
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(http://creativecommons.org/publicdomain/zeimmune system in many ways [6, 7]. It enhances
leukocyte function and innate immune responses via
modulation of chemokinesis and chemotaxis [8]. Leuko-
cytes actively accumulate ascorbate to achieve intracellu-
lar concentrations that exceed plasma concentrations by
up to 80-fold [9].
Cancer patients are often reported to be vitamin C
deficient [10–18]. Particularly serious are the deficiencies
in patients with advanced cancer [15, 19, 20], where
decreased plasma ascorbate levels are associated with
shorter survival and impaired quality of life [21].
Intravenous (iv) instead of oral administration of
ascorbate is required in order to achieve the high plasma
concentrations [22] that have been shown to havele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Table 1 Patient data eligibility criteria
Inclusion criteria
Aged ≥18
Vitamin C deficiency (due to the underlying cancer disease or
treatment)
Previously confirmed cancer diagnosis with previous or current
radiation- and/or chemotherapy
Total lymphocyte count <1500/μL
Treatment with iv vitamin C 7.5 g once a week, for a total of 4 doses
Patient's statement of agreement to use and publish their data for
the observational study
Exclusion criteria (anamnestic)
Patients who received colony-stimulating factor
Patients not completing all four doses of iv vitamin C
Oxalate-urolithiasis, nephrolithiasis
Renal insufficiency
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dose vitamin C (as sodium ascorbate) was found to have
selective tumour cytotoxic effects [25] and its chemo-
therapeutic potential is still undergoing investigation
[26]. Several phase I/IIa studies examined the chemo-
therapeutic effects of iv high-dose vitamin C as an adju-
vant to standard treatment in patients with advanced
tumours [27–29]. Another potential benefit of iv vitamin
C treatment is the favourable effect on the quality of life
of cancer patients [30–32]. Although iv high dose
vitamin C is a popular complementary treatment in the
management of cancer conditions [23, 24, 33], there is,
as far as we are aware, no published data on its effects
on lymphopenia.
The aim of this observational study was the evaluation
of the effects of iv high-dose vitamin C on lymphopenia
in cancer patients.
Methods
The objective of this prospective observational study was
to document the use of Pascorbin® 7.5 g (licensed, pro-
prietary medicinal product containing 7.5 g ascorbate
for iv infusion; license owner: Pascoe Pharmazeutische
Präparate GmbH, Germany) in patients with advanced
cancer and lymphopenia, and to monitor its effect on
their TLC. Data were collected from those cancer pa-
tients attending the ambulatory service of the Clinical
Nutrition Department at SOLCA Cancer Hospital,
Guayaquil, Ecuador, from February 2012 to October
2014, and who received elective iv ascorbate treatment
as an adjuvant to tumour therapy. It was the physicians’
decision to use the infusion in accordance to the indi-
cation as an adjuvant to tumour therapy with the aims
of to speed up postoperative recovery, to reduce the
side effects of conventional oncological therapy (such
as chemotherapy, radiotherapy), to reduce periods of
hospitalization, to prolong the tumour- and recurrence-
free intervals and to improve quality of life. As lymphope-
nia is a chemotherapy or radiation related hematological
side effect, the treatment with iv vitamin C is covered by
the approved indication.
The study included 48 cancer patients (aged ≥18 years)
with lymphopenia, defined as a TLC below 1500/μL
blood [2, 34]. Diagnosis of cancer was previously con-
firmed and documented by the attending physician.
Malignant neoplasm of cervix uteri (n = 11) was the
most common (22.9%) cancer documented in the
study group, followed by breast cancer (14.6%), with
between 2.1 and 8.3% for other cancer types. The
study was a non-interventional study aimed to docu-
ment the routine clinical use of iv vitamin C. Patients
agreed, in a signed statement, to study participation
and to release of their data. The criteria for patient
selection are listed in Table 1.Once a week, patients received iv vitamin C 7.5 g (Pas-
corbin®), diluted in a suitable carrier solution, such as
100 mL NaCL 0.9%. Data were collected before the start
of vitamin C treatment (visit 1, baseline) and after
4 weeks of treatment.Total lymphocyte count (TLC)
The main study parameter was the change in TLC from
baseline to 4 weeks. A quantitative multi-parameter
automated hematology analyser (xn 3000 series, sysmex)
was used for all patients to measure TLC in peripheral
blood samples obtained by venipuncture. The one-
sample t-test (two-sided, with α = 0.05) was used to test
for significance of the mean change. Additional, separate
analyses were carried out on data from patients with
TLC of <1000/μL (severe lymphopenia) and patients
with TLCs of 1000–1500 lymphocytes/μL before start of
treatment. The statistical analyses were performed by an
independent statistician.Nutritional status
Due to the lack of an universally accepted definition of
malnutrition, our classification of the nutrition status
(Table 2) is based on a combination of patient’s body
mass index (BMI) [35] together with a scored Patient-
Generated Subjective Global Assessment (PG-SGA) [36],
and the Nutritional Risk Screening (NRS) [37]. The BMI
allows us to classify overweight or obese patients. Risk of
malnutrion (BMI < 20.5) is defined by NRS and the
combination of BMI with the PG-SGA allows us to
Table 2 Baseline demographic and clinical characteristics of
patients
Characteristics Baseline/Visit 1 (n = 48)
Age, years mean ± SD; range
Total 56.4 ± 15.7; 17–84
Male 53.8 ± 15.4; 17–73




Nutrition status, n (%)
Normal 0 (0.0%)
Risk of malnutrition 10 (20.8%)
Mild malnutrition 3 (6.3%)
Moderate malnutrition 17 (35.4%)
Severe malnutrition 12 (25.0%)
Overweight 2 (4.2%)
Obesity Grade 1 4 (8.3%)
Table 3 Total lymphocytes count (TLC) at start and at end of treatm




All patients n = 48






25% Percentile 532.5 742.5
50% Percentile (Median) 920.0 1135.0
75% Percentile 1315.0 1440.0
Patients with severe lymphopenia (lymphocytes < 1000/μL) n = 25






25% Percentile 390.0 585.0
50% Percentile (Median) 540.0 820.0
75% Percentile 705.0 1180.0
Patients without moderate lymphopenia (lymphocytes 1000–1500/μL) n = 23
Mean value ± SD
range
1283 ± 161; 1000–1499 1323 ±
220–18
25% Percentile 1120.0 1150.0
50% Percentile (Median) 1320.0 1400.0
75% Percentile 1180.0 1620.0
SD standard deviation
aThe one-sample t-test (two-sided) with α = 5% was applied for statistical testing of
treatment are equal to 0
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malnutrition.
The safety of the vitamin C treatment was assessed by
the attending physician in terms of adverse events and
possible relatedness of such events to vitamin C
treatment.
Results
A total of 48 patients (mean ± standard deviation of age,
56.4 ± 15.7 years; 79.2% female) with previously con-
firmed neoplasms were included in the study and all
were included in our analysis. Of note, more than half of
the patients (60.4%) displayed moderate or severe
malnutrition (Table 2). The mean TLC increased sig-
nificantly (p = 0.0018) from 902.0/μL (±414/μL) at
baseline to 1113/μl (±466/μL) after 4 weeks treat-
ment. This was a mean increase in TLC of 211/μL
(±442/μL). In patients with <1000 lymphocytes/μL
(severe lymphopenia), the mean increase at 4 weeks
was 368/μL (±449/μL) (p = 0.0004) compared to an in-
crease of 40/μL (±372/μL) (p = 0.6105) in patients with an
initial TLC of 1000–1500 lymphocytes/μL (n = 23)
(Table 3).
Patients in our study group who were at risk of malnutri-
tion or mild malnutrition had initial TLC values of >1000/
μL (mean TLC 1046.9/μL and 1270.0/μL, respectively),
whereas the initial mean TLC in patients with moderate or






























the null hypothesis that the mean changes between start and after 4 weeks of
Fig. 1 Total lymphocytes count (TLC) before and after 4-week iv
high-dose vitamin C treatment. The Box Plot displays the data of the
study group with initial TLC < 1000 μL. Vertical bar indicates standard
deviation, box indicates 25%, median, 75% percentile
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treatment for each patient are available in Table 5.
In the study group, no adverse effects related to iv
vitamin C were observed.
Discussion
Our non-interventianal study provides evidence that iv
high-dose vitamin C reverses lymphopenia in cancer
patients. We included radiotherapy- or chemotherapy-
treated cancer patients with a TLC of <1500/μL, which
was our definition of lymphopenia [2]. The data indicated
a significant increase in the mean TLC value for the whole
group while a subgroup analysis revealed a more signifi-
cant effect in patients with a TLC of <1000/μL.
Several published reports suggest that lymphopenia is
a reversible, predictive factor for earlier tumour progres-
sion/relapse and reduced survival, as indicated in several
retrospective studies [3–5, 38, 39]. Poor prognosis of
cancer patients is indicated by a TLC value of <1000/μL
[39] [38] and is more evident with TLC values of <500/
μL [3, 5]. More than 35% of our patients with an initial
mean TLC of 551/μL (±212) had a TLC of >1000/μL
after 4 weeks of iv vitamin C treatment. Given the
increased risk of progression and mortality in severe
lymphopenia, a TLC increase to >1000/μL is a clinically
relevant and significant improvement.
The reasons for lymphopenia can be diverse [40]. In
our study group, it is presumably lymphocyte depletion
primarily due to radiotherapy and chemotherapy [40].
Severe stress, malnutrition and protein-energy under-
nutrition can also cause lymphopenia [2]. Moderate-to-
severe malnutrition was evident in more than half of the




























Valid data 48 48 48
Missing data 0 0.0 0
anegative values means a decrease of lymphocytescontributory factor to the lymphopenia. The small size
of our study group may explain the absence of statistical
significance of any association between nutritional status
and lymphocyte counts at the start of treatment. How-
ever, we did observe a correlation between risk of mal-
nutrition and lymphopenia in our study group (Table 4
and Fig. 1).
The beneficial effect of iv vitamin C on TLC values in
cancer patients is most likely due to its antioxidant actions
counteracting treatment-induced oxidative stress. This
was also suggested to explain the positive clinical effects
of iv high-dose vitamin C observed in other cancer pa-
tients [29, 30, 41]. Oxidative stress is considered to be an
underlying cause of lymphopenia of different etiologies
[42], such as that caused by intensive exercise [43], end-
stage renal disease patients [44] and AZT (3′-azido-2′,3′-
dideoxythimidine) (an AIDS treatment). This notion is
supported by animal data showing that high-dose antioxi-
dants abrogate experimentally-induced lymphopenia [45].
A contributory factor for the favourable effect of vita-
min C could be its function as a cofactor in the synthesis
carnitine [46], which supports immune cell function, s
predominantly through carnitine-dependent energy me-
tabolism of fatty acids. Carnitine deficiency has been
demonstrated in patients with impaired immune responses
[47]. The ability of vitamin C to increase endogen carnitine
synthesis and thereby improving energy metabolism is
supported by animal data [46].
The supportive effect of iv vitamin C on the immune
system that we have observed is supported by other









1430 1450 20 ≥1000
1330 220 −1110 ≥1000
880 1460 580 <1000
520 2420 1900 <1000
1499 1620 121 ≥1000
1300 1400 100 ≥1000
680 920 240 <1000
700 740 40 <1000
1250 1320 70 ≥1000
1440 1620 180 ≥1000
1350 1630 280 ≥1000
1130 460 −670 ≥1000
420 880 460 <1000
810 770 −40 <1000
1410 1330 −80 ≥1000
550 1280 730 <1000
130 510 380 <1000
1060 910 −150 ≥1000
290 1030 740 <1000
1490 1580 90 ≥1000
440 1080 640 <1000
660 680 20 <1000
960 1060 100 <1000
1120 1230 110 ≥1000
580 750 170 <1000
1420 1710 290 ≥1000
760 1310 550 <1000
370 380 10 <1000
1080 1690 610 ≥1000
280 1410 1130 <1000
830 720 −110 <1000
630 1290 660 <1000
1250 1380 130 ≥1000
1030 1180 150 ≥1000
1000 1120 120 ≥1000
1420 1670 250 ≥1000
530 570 40 <1000
1100 1150 50 ≥1000
380 400 20 <1000
490 510 20 <1000
710 820 110 <1000
400 440 40 <1000
540 940 400 <1000
Table 5 TLC at begin and end of treatment for each patient
(Continued)
1210 1870 660 ≥1000
1320 1400 80 ≥1000
1450 1500 50 ≥1000
1420 990 −430 ≥1000
240 600 360 <1000
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cell activity by high dose vitamin C [48]). Furthermore,
our data may relate to the increased quality of life and
prolonged survival time observed in in phase I/IIa clinical
trials of cancer patients treated with iv vitamin C [28, 29].
Intravenous high-dose vitamin C treatment was well
tolerated by our patients, which is consistent with data
from other clinical studies and comprehensive clinical
surveys indicating the good tolerability of iv high-dose
vitamin C up to 0.5 g/kg body weight (in phase-I-trials
even up to 1.5 g/kg) when contraindications are
complied with [23, 27, 33, 49, 50].
As we are aware, our study provides the first evidence
that iv high-dose vitamin C treatment improves the im-
mune status of cancer patients treated in daily clinical
practice, and that the treatment is well-tolerated by this
patient group. However, the clinical interpretation of our
data is limited by the absence of a control group and the
small size of our study group.
Conclusion
This study provides “real-life” observational evidence of
the use of iv high-dose vitamin C in daily practice in the
treatment of cancer patients with lymphopenia. Patients
with severe lymphopenia seem to particularly benefit
from iv vitamin C with a clinically significant increase
in TLC. Appropriately-powered, randomized, placebo-
controlled trials of iv high-dose vitamin C are now
needed to define more precisely its role in the treatment
of cancer-related lymphopenia and how this impacts on
the patients’ clinical prognosis.
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